![]() |
Volumn 9, Issue 6, 2000, Pages 439-445
|
Controversies in experimental dermatology. What is the most promising strategy for the treatment of metastasizing melanoma? Viewpoints
a
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ALPHA INTERFERON;
BETA INTERFERON;
CARMUSTINE;
CISPLATIN;
DACARBAZINE;
GLYCOPROTEIN GP 100;
INTERLEUKIN 2;
LIPOSOME;
MELANOMA ANTIGEN;
SYNTHETIC PEPTIDE;
TAMOXIFEN;
VINBLASTINE;
CANCER CHEMOTHERAPY;
CANCER IMMUNOTHERAPY;
CANCER SURVIVAL;
CLINICAL TRIAL;
DENDRITIC CELL;
DOSE RESPONSE;
DRUG POTENTIATION;
DRUG RESPONSE;
DRUG SCREENING;
EXPERIMENTAL MODEL;
GENE THERAPY;
GENETIC TRANSDUCTION;
HEALTH CARE COST;
HUMAN;
LIFE EXPECTANCY;
LYMPH NODE DISSECTION;
LYMPH NODE METASTASIS;
MELANOMA;
METASTASIS;
NONHUMAN;
NOTE;
SURGICAL TECHNIQUE;
ARTICLE;
IMMUNOTHERAPY;
PALLIATIVE THERAPY;
PATHOLOGY;
SKIN TUMOR;
HUMANS;
IMMUNOTHERAPY;
MELANOMA;
NEOPLASM METASTASIS;
PALLIATIVE CARE;
SKIN NEOPLASMS;
|
EID: 0033708677
PISSN: 09066705
EISSN: None
Source Type: Journal
DOI: 10.1034/j.1600-0625.2000.009006439.x Document Type: Note |
Times cited : (19)
|
References (76)
|